Should I Buy CPRX? CPRX 2026 Analysis

Should You Buy Catalyst Pharmaceuticals Inc (CPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

24.580

1 Day change

1.57%

52 Week Range

26.580

Analysis Updated At

2026/01/28

Buy CPRX now for a beginner, long-term investor with $50k–$100k. The chart trend is bullish (stacked moving averages and positive MACD), fundamentals show solid Q3 2025 growth with very high margins, and Wall Street targets ($33) imply meaningful upside from $24.25. Intellectia signals are not active today, but the overall technical + fundamental setup still supports buying immediately rather than waiting for a perfect dip. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Technical Analysis

Trend is bullish: SMA_5 > SMA_20 > SMA_200 confirms an uptrend. MACD histogram is positive (0.122) and expanding, supporting continued upward momentum. RSI(6) at ~63.96 is bullish-leaning but not overbought, suggesting room to run. Key levels: support near Pivot 23.60 (then S1 22.63); resistance near R1 24.57 and R2 25.16. With price at 24.25, CPRX is closer to resistance than support, but the trend still favors buying over selling.

Options Data

Bullish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Options positioning looks roughly balanced to slightly call-leaning on open interest (0.92 < 1), while same-day volume is neutral (put/call volume ratio ~1.0) with unusually low absolute volume today (34 vs 5D/10D averages). Implied volatility is elevated (30D IV ~51% vs historical ~34%), indicating the market is pricing meaningful movement risk, but not showing a strong directional consensus from volume today.

Technical Summary

Sell

Buy

Positive Catalysts

News flow highlights strong multi-year growth and notes Catalyst’s debt-free balance sheet, which can support flexibility for R&D and potential acquisitions; broader biotech sector tone has been improving (per sector ETF recovery commentary).

Neutral/Negative Catalysts

Near-term trading expectations from the provided pattern model are modest to negative beyond the next day (next week/month bias slightly down), which could mean choppy consolidation. Price is approaching nearby resistance (24.57–25.16), increasing the chance of short-term pullbacks. Options IV is elevated, reflecting higher uncertainty around future moves.

Financial Performance

Latest reported quarter: 2025/Q3. Performance is strong and improving: revenue $148.392M (+15.31% YoY), net income $52.783M (+20.28% YoY), EPS $0.42 (+20.00% YoY), and gross margin ~78.44% (+0.87% YoY). This is a healthy growth profile with excellent profitability for a long-term hold.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is positive: on 2025-11-07 both Oppenheimer (Outperform) and Citi (Buy) raised price targets to $33 (from $32 and $31, respectively) after a Q3 revenue beat and strong profitability. Wall Street pros: consistent profitability, strong growth, and upward revisions/targets. Cons: with the stock already in an uptrend and near resistance, some upside may rely on continued execution and future catalysts rather than a cheap entry. Politician/congress activity: no recent congress trading data available; hedge fund and insider trend data are neutral with no notable recent activity.

5 Analyst Rating

Wall Street analysts forecast CPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CPRX is 34 USD with a low forecast of 33 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.200

Low

Averages

High

Current: 24.200

Low

Averages

High

Oppenheimer

Leland Gershell

Outperform

maintain

$32 -> $33

AI Analysis

2025-11-07

Reason

Oppenheimer

Leland Gershell

Price Target

$32 -> $33

AI Analysis

2025-11-07

maintain

Outperform

Reason

Oppenheimer analyst Leland Gershell raised the firm's price target on Catalyst Pharmaceuticals to $33 from $32 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 total revenue of $148.4M, coming in well above its/consensus estimates of $136M/$137M and driving non-GAAP net income of $86.1M.

Citi

Buy

maintain

$31 -> $33

2025-11-07

Reason

Citi

Price Target

$31 -> $33

2025-11-07

maintain

Buy

Reason

Citi raised the firm's price target on Catalyst Pharmaceuticals to $33 from $31 and keeps a Buy rating on the shares. The firm sees the upper end of the company's 2025 outlook as potentially achievable following the Q3 report.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CPRX

Unlock Now

CPRX Should I Buy

CPRX Should I Buy

Should You Buy Catalyst Pharmaceuticals Inc (CPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch